FDA's First Biosimilar Approval Greeted with Optimism; Naming, Pricing Still Issues
March 9, 2015
John Aquino
Bloomberg BNA Life Science’s Law & Industry Report
Axinn Counsel Stacie Ropka was quoted in the Bloomberg BNA Life Science’s Law & Industry Report article, "FDA's First Biosimilar Approval Greeted with Optimism; Naming, Pricing Still Issues."
Click here to access the article.